Why Is PHARVARIS N V (PHVS) Stock Moving Today?

Why PHVS stock is up today

Pharvaris N.V. stock rose 6.37% to $39.90 on Wednesday, driven by positive developments in its clinical trials and a series of analyst upgrades. The company released topline results from a Phase III study of deucrictibant for the prophylactic treatment of hereditary angioedema. This was followed by Guggenheim raising its price target for the stock to $44 from $40. The stock opened with a 2.6% gap up and traded in a volatile range before settling near the session high.

What Happened

Pharvaris N.V. published a slide deck outlining the topline results of its Chapter-3 Phase III study on deucrictibant, a drug candidate for the treatment of hereditary angioedema. This milestone in the clinical development of the drug was followed by an analyst action from Guggenheim, which raised its price target to $44. Additional external context came from other analysts, including Morgan Stanley, Leerink Partners, and RBC Capital, who also raised their price targets for the stock. These developments contributed to the stock’s strong performance on Wednesday.

What The Data Shows

The stock opened at $38.50, a 2.6% gap up from the prior close of $37.51. It reached a session high of $40.34 at 9:50 AM ET before retreating slightly. The stock closed at $39.90, with a volume of 0.1M shares, which is 0.2 times the 3-month daily average. Over the past 8 sessions, the stock has gained 9.5%, rising from $34.63 to $37.93. Additionally, the 52-week tape showed 10 fresh 52-week highs and one fresh 52-week low on the same day. Insider transactions in the last 90 days totaled $6.1M in sales, with no insider buying activity.

What To Watch

Pharvaris N.V. has no scheduled earnings date in the immediate future. Investors should monitor the breadth of analyst coverage and any further developments in the company’s clinical trials or regulatory process.